Arkolith/Insider Trading/KURA/Form 4

Doyle Thomas James

SVP, Finance & AccountingKura Oncology, Inc. (KURA) · full profile →Form 4 · filed Jan 27, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$60K
Net Open-Market Flow
-$60K
Transactions
5
5 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 27, 2026Sell(S)1K$8.46$9K149K
Jan 27, 2026Sell(S)695$8.46$6K148K
Jan 27, 2026Sell(S)2K$8.46$19K146K
Jan 27, 2026Sell(S)881$8.46$7K145K
Jan 27, 2026Sell(S)2K$8.46$19K150K

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-26-025302) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML